TIDMCOG
RNS Number : 3792M
Cambridge Cognition Holdings PLC
21 September 2021
21 September 2021
Cambridge Cognition Holdings Plc
("Cambridge Cognition", the "Company" or the "Group")
Interim Results for the six months ended 30 June 2021
Cambridge Cognition Holdings Plc (AIM: COG), which develops and
markets digital solutions to assess brain health, is pleased to
announce its unaudited interim results for the six months ended 30
June 2021.
The Company had a strong and profitable first half, delivering
revenues of GBP4.5 million, a 50% year-on-year growth. Order intake
was above the Board's expectations at GBP8.6 million and this
included two substantial orders outside the Company's core area of
focus that totalled GBP3.6 million.
The Company is now delivering more clinical trial contracts than
at any time in its history, which is reflected in a contracted
order book at 30 June 2021 of GBP15.2 million, up 36% from 31
December 2020 and more than double the value at 30 June 2020. The
order book contains contracts for clinical trials in which revenue
will be recognised over one to six years, further increasing the
long-term revenue base for the Company. The forward order pipeline
provides a good platform for growth, though at this time does not
include the unusually large orders seen in the last two half-year
periods.
The direct impact of COVID-19 on the Company's operations has
been minimal and the Company continued to deliver high levels of
customer service while operating in a remote manner. The pandemic
has accelerated interest in virtual clinical trials, with testing
performed at home rather than in-clinic, and, as a result, orders
for home testing solutions grew. We expect this trend to persist
after the pandemic.
Looking forward, the Board believes the Company to be well
positioned as a digital technology solutions provider, underpinned
by a strong cash position. The Company will continue to take
advantage of the growth in interest in developing new
pharmaceuticals for Central Nervous Systems ("CNS") disorders and
the market shift to virtual clinical trials, continuing to focus on
commercial execution and investment in new products to expand the
product offer for future growth.
Financial highlights
-- 50% year-on-year revenue growth to GBP4.5 million (H1 2020:
GBP3.0 million)
-- Gross margin maintained at 80% (H1 2020:81%)
-- Profit for the period GBP0.1 million (H1 2020: GBP0.4 million
loss)
-- 0.3p basic and diluted earnings per share (H1 2020: 1.5p loss
per share)
-- Strong cash generation with cash balance of GBP4.2 million
(31 December 2020: GBP3.0 million)
Operational highlights
-- Increase in sales orders of 74% to GBP8.6 million (H1 2020:
GBP4.9 million)
-- Contracted order book of GBP15.2 million, up 36% since 31 December
2020 and more than double the value at 30 June 2020 (31 December
2020: GBP11.2 million, 30 June 2020: GBP7.4 million)
-- Launch of NeuroVocalix(TM), a digital voice cognition solution,
ready for clinical trials
-- Completed successful spin-out and venture financing of Monument
Therapeutics
Commenting on the results Matthew Stork, Chief Executive Officer
of Cambridge Cognition, said: "I am delighted with our performance
over the first half of the year. We have continued to execute our
growth strategy, achieving a number of firsts, including the
highest order intake in a six-month period. The Company is well
positioned to serve pharmaceutical companies, whose needs are
changing as the benefits of virtual clinical trials are embraced
globally. We continue to attract interest from a wide range of
customers and remain confident in the outlook for the year."
Enquiries:
Cambridge Cognition Holdings Plc Tel: 01223 810 700
Matthew Stork, Chief Executive Officer press@camcog.com
Michael Holton, Chief Financial Officer
finnCap Ltd (Nomad and Joint Broker) Tel: 020 7220 0500
Geoff Nash / Simon Hicks (Corporate Finance)
Alice Lane / Charlotte Sutcliffe (Corporate Broking)
Dowgate Capital Limited (Joint Broker) Tel: 020 3903 7715
David Poutney / James Serjeant
IFC Advisory Ltd (Financial PR and Tel: 020 3934 6630
IR)
Tim Metcalfe / Graham Herring / Zach cog@investor-focus.co.uk
Cohen
The information communicated in this announcement contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) No. 596/2014.
CHIEF EXECUTIVE OFFICER'S REVIEW
Overview
The Company delivered an exceptionally strong financial and
operational performance in the first half of 2021, with a further
considerable increase in secured orders and successful delivery of
new contracts won in 2020 and early 2021. Progress against our
strategy to focus on commercialisation of existing and newly
developed products continues to be delivered.
Orders received totalled GBP8.6 million (H1 2020: GBP4.9
million). These contracts included a number of major wins for
CANTAB(TM) cognitive assessment software, many for at-home use.
This is in line with our expectations of a market shift to virtual
trials catalysed by the COVID-19 pandemic.
Around two-thirds of the Company's clinical trial orders came
from existing customers, reflecting excellent customer service and
the benefits of the Company's focus on commercialisation. These
sales orders cover a range of cognitive assessments across various
clinical trial phases, demonstrating the Company's ability to
deliver against a spectrum of client needs with a broader
portfolio.
As well as a record sales orders achievement in the first half,
I am pleased to report more firsts for Cambridge Cognition in the
period. These include:
-- The achievement of a strategic goal by securing an evergreen
contract for post-marketing support for a newly licensed pharmaceutical
with a top twenty pharma company
-- Contract wins in a number of new therapeutic areas; examples
include a COVID-19 study measuring the impact of the virus
on cognition and an oncology study measuring the neurological
effects of brain metastases and chemotherapy agents
-- The Company's largest funded clinical trial, assessing many
thousands of patients at home with a mixture of longer web-based
assessments and high-frequency, quick assessments on mobiles
-- The provision of NeuroVocalix(TM), a unique digital voice solution
that can conduct common verbal cognitive tests on our regulatory-compliant
clinical trial platform
Cambridge Cognition is focused on successful operational
delivery to meet today's customer needs, while investing, as is
critical for a growing technology business, to meet their future
requirements. During the period, the business continued to invest
through R&D initiatives and increased headcount across the
business to deliver against an increased sales order book whilst
looking to drive future growth.
Financial results
Sales orders of GBP8.6 million (H1 2020: GBP4.9 million)
contributed to further growth in the Company's contracted order
book, which has more than doubled from GBP7.4 million at 30 June
2020 to GBP15.2m at 30 June 2021. The contracted order book
represents confirmed orders that are not yet recognised as
revenue.
Revenue, which is recognised as software products and associated
services are used, grew to GBP4.5 million (H1 2020: GBP3.0
million), a 50% increase and ahead of our initial forecasts for H1
2021. This represents further good growth from GBP2.2 million in H1
2019, a period not impacted by the pandemic.
The key components of revenue are shown in the table below:
Revenue (GBPm) H1 2021 H1 2020 H1 2019
Software & services 4.3 2.9 2.2
-------- -------- --------
Hardware 0.2 0.1 -
-------- -------- --------
Total 4.5 3.0 2.2
-------- -------- --------
Software & services revenue increased by 47% to GBP4.3
million due to the increased number and value of contracts being
delivered. Hardware revenue remains a small proportion of the sales
mix, though may increase over time as it is possible that the
Company supports more trials using wearables.
Gross profit rose by GBP1.1 million to GBP3.6 million (H1 2020:
GBP2.5 million) and the gross profit margin of 80% was broadly in
line with the prior year (H1 2020: 81%).
Administrative expenses increased by GBP0.7 million to GBP3.6
million (H1 2020: GBP2.9 million). Excluding the impact of foreign
currency, administrative expenses increased by GBP0.4 million to
GBP3.4 million (H1 2020: GBP3.0 million), reflecting investment in
personnel and increased activity. Focused R&D remains important
to continue to position the Company at the forefront of the sector,
with R&D investment of GBP0.8 million remaining broadly in line
with the prior year (H1 2020: GBP0.7 million) and reducing slightly
as a percent of revenue.
The rise in gross profit, partially offset by increased
administrative expenses, resulted in a profitable first half.
Profit before tax, Profit for the period and EBITDA all rose by
GBP0.5 million. Consequently, basic and diluted earnings per share
improved to 0.3p (H1 2020: 1.5p loss on a basic and diluted
basis).
The excellent sales order performance combined with higher level
of revenues contributed to strong cash generation, with net cash
inflow from operations of GBP1.2 million (H1 2020: GBP0.2 million
outflow). This led to an overall improvement in cash to GBP4.2
million as at 30 June 2021.
Operational review
The Company's above expectation sales orders performance in H1
2021 demonstrated continued strong commercial execution. Over the
period, the business expanded its marketing and sales team to
increase coverage and support sales of the growing product
offering.
As with most technology businesses, continued R&D investment
in products is essential to support further growth in the future.
Progress has been good through the first half of 2021 with
developments in:
-- Prototypes of new tests designed for use primarily on mobile
phones
-- Services supporting multiple clinical trials with wearable
devices, providing richer data for clients
-- Platform development to enable the delivery of a solution for
a newly licensed pharmaceutical
-- The production release, further development and planned clinical
validation of NeuroVocalix(TM)
-- Movement of our infrastructure to Amazon Web Services in multiple
geographies
Providing a high level of customer service remains an important
element of our offering. Making operational improvements has been
important over the period and we have continued to deliver projects
on time for customers and received excellent customer feedback. We
are now working on over 30% more projects with a 20% increase in
service staff compared to June 2020.
Corporate development
During the period, the Company completed the spin-out of
Monument Therapeutics Limited ("Monument"), a drug development
company applying digital phenotyping to CNS disorders which
Cambridge Cognition had been incubating since 2018, with
early-stage research supported by two Innovate UK grants. Monument
applies a novel drug development strategy, leveraging digital
assessments of cognition, to match patients with new pharmaceutical
treatments.
To develop these programmes as an independent company, Monument
secured GBP2.6 million in funding from a consortium of investors
led by Catapult Ventures and Neo Kuma Ventures. Cambridge Cognition
retained a 36.9% shareholding and agreed a licence for the use of
several of the Company's gold-standard cognitive assessments,
including CANTAB(TM), for patient stratification. Upon successful
commercialisation of its drug development programmes, Monument will
pay royalties to Cambridge Cognition.
Cambridge Cognition is yet to finalise the accounting treatment
for Monument. Costs incurred by Cambridge Cognition prior to the
spin-out have been disclosed as "Investment" and "Cost of
investment" in the balance sheet and cash flow, respectively, for
the purposes of this Report.
Board changes
As previously announced, Michael (Mick) Holton, CFO, was
appointed as a Board Director at the AGM. Nick Walters, former CFO,
continued as an Executive Director until the AGM to conduct a
handover with Mick. We are pleased to have Mick on board and are
grateful to Nick for seven years' dedicated service.
Outlook
The clinical trials market that the Company serves is large and
evolving rapidly, with many drivers of change supporting potential
future growth. The market for electronic clinical outcomes
assessments is estimated at over US$1bn p.a. and growing at 15%, a
trajectory which may increase in pace as a result of:
-- a catalytic effect of the COVID-19 pandemic, with growing evidence
that this is likely to be accelerating a move to more virtual
clinical trials; and
-- technological innovation enabling real-world testing and data
capture, which often has meaningful advantages over testing
and data captured in-clinic
Cambridge Cognition's core strength is in supporting clinical
trials for CNS disorders, though the Company, at times, wins
contracts in other therapy areas based on its technology,
reputation and levels of service. Pharmaceutical companies are
investing more in therapeutics for CNS disorders, with a 20%
increase in number of industry sponsored clinical trials from 2020
to 2021, likely underpinned by exciting new drug developments and
the approval of a new drug for Alzheimer's disease.
The Company remains firmly on track and we continue to trade in
line with market expectations. We continue to see potential for
growth for both clinic-based and virtual assessments for cognition,
whether for recognised solutions such as CANTAB(TM), or for newer
high-frequency digital or voice-based assessments and for
electronic Clinical Outcomes Assessment solutions for CNS disorders
in clinical trials.
With increasing investment in commercial activities, continued
product development, a rising cash balance and supportive
shareholder base, the Company is well positioned for further
revenue growth. We remain excited about the potential for the
future.
Matthew Stork
Chief Executive Officer
21 September 2021
CONDENSED CONSOLIDATED COMPREHENSIVE INCOME STATEMENT
For the six months ended 30 June 2021
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
------------ ------------ -------------
Revenue 5 4,500 3,010 6,741
Cost of sales (885) (559) (1,324)
------------ ------------ -------------
Gross profit 3,615 2,451 5,417
Administrative expenses (3,529) (2,900) (6,093)
Other income - 26 32
Finance costs (2) (5) (5)
------------ ------------ -------------
Profit / (loss) before tax 84 (428) (649)
Tax - 4 211
------------ ------------ -------------
Profit / (loss) for the period 84 (424) (438)
============ ============ =============
Earnings / loss per share (pence) 6
Basic 0.3 (1.5) (1.5)
Diluted 0.3 (1.5) (1.5)
All amounts are attributable to equity holders in the
parent.
Profit / (loss) for the period 84 (424) (438)
Other comprehensive income - items
that may be reclassified subsequently
to profit or loss:
Exchange differences on translation
of foreign operations 51 (153) 93
---- ------ ------
Total comprehensive income / (expense)
for the period 135 (577) (345)
==== ====== ======
Consolidated statement of financial position
At 30 June 2021
At 30 June At 30 June At 31 December
2021 2020 2020
Unaudited Unaudited Audited
GBP'000 GBP'000 GBP'000
----------- ----------- ---------------
Assets
Non-current assets
Intangible assets 376 382 379
Property, plant and equipment 105 69 138
Investment 7 49 - -
Total non-current assets 530 451 517
Current assets
Inventories 138 47 51
Trade and other receivables 5,025 2,529 2,648
Cash and cash equivalents 4,168 1,959 3,047
----------- ----------- ---------------
Total current assets 9,331 4,535 5,746
----------- ----------- ---------------
Total assets 9,861 4,986 6,263
=========== =========== ===============
Liabilities
Current liabilities
Trade and other payables 9,600 5,163 6,206
Total liabilities 9,600 5,163 6,206
----------- ----------- ---------------
Equity
Share capital 312 312 312
Share premium 11,151 11,151 11,151
Other reserves 6,162 5,865 6,111
Own shares (78) (81) (78)
Retained earnings (17,286) (17,424) (17,439)
----------- ----------- ---------------
Total equity / (shareholders'
deficit) 261 (177) 57
----------- ----------- ---------------
Total liabilities and equity 9,861 4,986 6,263
=========== =========== ===============
Consolidated statement of changes in equity
Share Share Other Own Retained
capital premium reserve shares earnings Total
GBP'000 GBP'000 GBP'000 GBP'000 GBP'000 GBP'000
------------------------ --------- --------- --------- -------- ---------- --------
Balance at 1 January
2020 242 9,943 6,018 (81) (17,066) (944)
Loss for the period - - - - (424) (424)
Other comprehensive
expense - - (153) - - (153)
--------- --------- --------- -------- ---------- --------
Total comprehensive
expense for the
period - - (153) - (424) (577)
--------- --------- --------- -------- ---------- --------
Issue of new share
capital 70 1,330 - - - 1,400
Share issue costs - (122) - - - (122)
Credit to equity
for share-based
payments - - - - 66 66
--------- --------- --------- -------- ---------- --------
Transactions with
owners 70 1,208 - - 66 1,344
--------- --------- --------- -------- ---------- --------
Balance at 30 June
2020 312 11,151 5,865 (81) (17,424) (177)
Balance at 1 July
2020 312 11,151 5,865 (81) (17,424) (177)
Loss for the period - - - - (14) (14)
Other comprehensive
income - - 246 - - 246
--------- --------- --------- -------- ---------- --------
Total comprehensive
income / (expense)
for the period - - 246 - (14) 232
--------- --------- --------- -------- ---------- --------
Transfer on allocation
of shares held
in trust - - - 3 (3) -
Credit to equity
for share-based
payments - - - - 2 2
--------- --------- --------- -------- ---------- --------
Transactions with
owners - - - 3 (1) 2
--------- --------- --------- -------- ---------- --------
Balance at 31 December
2020 312 11,151 6,111 (78) (17,439) 57
------------------------ --------- --------- --------- -------- ---------- --------
Balance at 1 January
2021 312 11,151 6,111 (78) (17,439) 57
Profit for the
period - - - - 84 84
Other comprehensive
income - - 51 - - 51
--------- --------- --------- -------- ---------- --------
Total comprehensive
income for the
period - - 51 - 84 135
Credit to equity
for share-based
payments - - - - 69 69
--------- --------- --------- -------- ---------- --------
Transactions with
owners - - - - 69 69
--------- --------- --------- -------- ---------- --------
Balance at 30 June
2021 312 11,151 6,162 (78) (17,286) 261
--------- --------- --------- -------- ---------- --------
Consolidated statement of cash flows
For the 6 months ended 30 June 2021
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
Unaudited Unaudited Audited
Note GBP'000 GBP'000 GBP'000
------------ ------------ -------------
Net cash flows from operating activities 8 1,236 (163) 1,010
Investing activities
Interest on bank deposits - 2 4
Purchase of property, plant and
equipment (38) (22) (42)
Cost of investment 7 (49) - -
------------ ------------ -------------
Net cash flow used in investing
activities (87) (20) (38)
Financing activities
Proceeds from the issue of share
capital net of costs - 1,278 1,278
Lease payments (36) (57) (113)
------------ ------------ -------------
Net cash flows from financing activities (36) 1,221 1,165
Net increase in cash and cash equivalents 1,113 1,038 2,137
Cash and cash equivalents at start
of period 3,047 901 901
Exchange differences on cash and
cash equivalents 8 20 9
------------ ------------ -------------
Cash and cash equivalents at end
of period 4,168 1,959 3,047
============ ============ =============
NOTES TO THE INTERIM FINANCIAL STATEMENTS
1. General information
Cambridge Cognition Holdings Plc (the "Company") and its
subsidiaries (together, 'the Group') develops and markets digital
solutions to assess brain health for sale worldwide, principally in
the UK, the US and Europe.
The Company is a public limited company quoted on the AIM market
of the London Stock Exchange (symbol COG) and is incorporated and
domiciled in the UK. The address of its registered office is
Tunbridge Court, Tunbridge Lane, Bottisham, Cambridge, CB25
9TU.
The condensed consolidated interim financial statements were
approved by the Board of Directors for issue on 21 September 2021.
The condensed consolidated interim financial statements do not
comprise statutory accounts within the meaning of section 434 of
the Companies Act 2006.
Statutory accounts of the Group for the year ended 31 December
2020 were approved by the Board of Directors on 27 May 2021 and
delivered to the Registrar of Companies. The report of the auditors
on those accounts was unqualified, did not contain an emphasis of
matter paragraph and did not contain any statement under section
498 of the Companies Act 2006.
The condensed consolidated interim financial statements together
with the comparative information for the six months ended 30 June
2020 have not been audited.
2. Basis of preparation
Going concern basis
The Group's forecasts and projections, taking account of
reasonably possible changes in trading performance, support the
conclusion that there is a reasonable expectation that the Group
has adequate resources to continue in operational existence for the
foreseeable future, a period of not less than twelve months from
the date of this report. The Directors also believe that the Group
is able to survive the consequences of reasonably forecastable
impacts of a resurgence of the COVID-19 pandemic. The Group
therefore continues to adopt the going concern basis in preparing
its condensed consolidated interim financial statements.
3. Accounting policies
The accounting policies adopted in the preparation of the
condensed consolidated interim financial statements are consistent
with those followed in the preparation of the Group's consolidated
financial statements for the year ended 31 December 2020.
4. Critical accounting judgments and key sources of estimation
uncertainty
In the application of the Group's accounting policies the
Directors are required to make judgments, estimates and assumptions
about the carrying amounts of assets and liabilities that are not
readily apparent from other sources. The estimates and associated
assumptions are based on historical experience and other factors
that are considered to be relevant. Actual results may differ from
these estimates.
The estimates and underlying assumptions are reviewed on an
ongoing basis.
The following are the critical judgments that the Directors have
made in the process of applying the Group's accounting
policies.
Revenue recognition
Judgments may be required in recognising revenue and cost. These
judgments include:
-- The extent to which, and the way in which, contracts are separated
into their component parts and the values attributed to those
parts;
-- Whether software licences are granted to allow the customer
the benefit of use of our intellectual property over a period
of time (including benefitting from future maintenance and
improvements) or whether that right is given as the intellectual
property exists at the point of time the licence is granted.
In the case of the former, software is recognised over the
period of use, for the latter revenue is recognised when the
licence commences and the customer is able to use the software;
-- The adoption of the portfolio approach for lower value sales
and the recognition criteria applied;
-- Where performance obligations are satisfied over time, the
length of time remaining for performance, and whether this
needs revising over time; and
-- The length of time for performance also dictates the initial
deferral and subsequent recognition of commissions in cost
of sales.
Goodwill
The Group reviews the carrying value of its goodwill balances by
carrying out impairment tests on at least an annual basis. These
tests require estimates to be made of the value in use of its CGUs
which are dependent on estimates of future cash flows and long-term
growth rates of the CGUs.
Capitalisation of development costs
The point at which development costs meet the criteria for
capitalisation is critically dependent on management judgment of
the probability of future economic benefits.
Recovery of deferred tax assets
Deferred tax assets have not been recognised for deductible
temporary differences, share options and tax losses as management
considers that there is not sufficient certainty that future
taxable profits will be available to utilise those temporary
differences and tax losses.
5. Segmental information
The analysis of revenue by product type is as follows:
6 months
to 30 June 6 months to Year to 31 December
2021 30 June 2020 2020
GBP'000 GBP'000 GBP'000
Software 1,374 1,310 2,751
Services 2,882 1,583 3,679
Hardware 244 117 311
4,500 3,010 6,741
============ ============== ====================
6. Earnings per share
Calculation of earnings / (loss) per share is based on the
following profit / (loss) and numbers of shares:
6 months 6 months Year to
to 30 June to 30 June 31 December
2021 2020 2020
GBP'000 GBP'000 GBP'000
Earnings
Earnings for the purposes of basic and
diluted earnings per share being net profit
/ (loss) attributable to owners of the
Company 84 (424) (438)
'000 '000 '000
Number of shares
Weighted average number of ordinary shares
for the purposes of basic EPS 31,097 28,429 29,776
Effect of dilutive share options 2,177 - -
------------ ------------ -------------
Weighted average number of ordinary shares
for the purposes of diluted EPS 33,274 28,429 29,776
------------ ------------ -------------
Pence Pence Pence
Earnings / (loss) per share
Basic 0.3 (1.5) (1.5)
Diluted 0.3 (1.5) (1.5)
The basic weighted average number of shares excludes shares held
by an Employee Benefit Trust. Fully diluted earnings per share is
calculated after showing the effect of outstanding options in
issue.
In prior periods presented, the effect of the options would be
to reduce the loss per share, and hence the diluted loss per share
is the same as the basic loss per share.
The number of shares in issue at 30 June 2021 was 31,170,903 (31
December 2020: 31,170,903).
7. Investment
On 30 June 2021, the Company completed the spin-out of Monument
Therapeutics Limited ("Monument"). Monument secured GBP2.6 million
in funding from a consortium of investors led by Catapult Ventures
and Neo Kuma Ventures. Cambridge Cognition retained a 36.9%
shareholding.
Cambridge Cognition is yet to finalise the accounting treatment
for Monument. Costs incurred by Cambridge Cognition prior to the
spin-out have been disclosed as "Investment" and "Cost of
investment" in the balance sheet and cash flow, respectively, for
the purposes of this Report.
8. Reconciliation of operating result to operating cash
flows
6 months 6 months
to 30 June to 30 June Year to 31
2021 2020 December 2020
GBP'000 GBP'000 GBP'000
Profit / (loss) before tax 84 (428) (649)
Adjustments for:
Depreciation of property, plant
and equipment 70 70 132
Amortisation of software licences 3 3 6
Share-based payments charge 69 66 68
Finance costs 2 5 9
Interest received - (2) (4)
Operating cash flows before
working capital movements 228 (286) (438)
Change in inventories (86) 6 2
Change in trade and other receivables (2,416) (917) (1,010)
Change in trade and other payables 3,512 1,027 2,243
------------ ------------ ---------------
Cash generated / (used) by operations 1,238 (170) 797
Taxation (paid) / received (2) 7 213
------------ ------------ ---------------
Net cash flows from operations 1,236 (163) 1,010
------------ ------------ ---------------
9. Copies of interim financial statements
Copies of the interim financial statements are available from
the Company at its registered office at Tunbridge Court, Tunbridge
Lane, Bottisham, Cambridge, CB25 9TU. The interim financial
information document will also be available on the Company's
website www.cambridgecognition.com .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IR FLFETAVIIFIL
(END) Dow Jones Newswires
September 21, 2021 02:00 ET (06:00 GMT)
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Cambridge Cognition (LSE:COG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
